

1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
- Aflibercept (**in combination with FOLFIRI = <5**)
 - Bevacizumab **0**
 - Capecitabine **7**
 - CAPIRI **Not in data**
 - CAPOX **10**
 - Cetuximab in combination with FOLFIRI **<5**
 - Cetuximab in combination with FOLFOX **0**
 - Cetuximab not in combination with FOLFIRI or FOLFOX **0**
 - Irinotecan **0**
 - FOLFIRI **0**
 - FOLFOX **0**
 - Oxaliplatin **0**
 - Panitumumab in combination with FOLFIRI **0**
 - Panitumumab in combination with FOLFOX **0**
 - Panitumumab not in combination with FOLFIRI or FOLFOX **0**
 - Nivolumab **Not in data**
 - Raltitrexed **0**
 - Ramucirumab **Not in data**
 - Regorafenib **Not in data**
 - Sorafenib **Not in data**
 - 5FU only **0**
 - Tegafur Uracil + 5FU **Not in data**
 - Trifluridine–tipiracil **0**
 - XELOX - **see under CAPOX which is the same regimen**
 - Other **FOLFOXIRI - <5**

Due to low numbers, less than 5 totals have been substituted for the actual data as this is deemed patient identifiable; therefore we are applying section 38(1)(b) of FOISA